Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients-Reference-Cited by-同舟云学术

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

Published:2014-11 Issue: Volume:17 Page:19532
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:Journal of the International AIDS Society

Author:

Gatell Josep M,Morales-Ramirez Javier O,Hagins Debbie P,Thompson Melanie,Keikawus Arasteh,Hoffmann Christian,Rugina Sorin,Osiyemi Olayemi,Escoriu Simona,Dretler Robin,Harvey Charlotte,Xu Xia,Teppler Hedy

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.7448/IAS.17.4.19532/fullpdf

Reference1 articles.

1. Morales-Ramirez J Gatell J Hagins D Thompson M Arastéh K Hoffmann C Safety & Antiviral Effect of MK-1439, a novel NNRTI, (+TDF/FTC) in ART-Naive HIV Infected Patients Conference on Retroviruses and Opportunistic Infections (CROI) 2014 Program and Abstracts [Abstr 92LB], March 2014, IAS-USA, San Francisco, CA

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine;Therapeutic Drug Monitoring;2023-12-26

2. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV;Journal of Antimicrobial Chemotherapy;2023-11-24

3. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV;BMC Infectious Diseases;2023-09-04

4. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

5. An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status;Infection & Chemotherapy;2021